SAN DIEGO – StemProtein LLC, a leading manufacturer of stem cell factors, and a recent spinout of Stemedica Cell Technologies Inc., announced today that it appoints Thomas H. Silberg as CEO of StemProtein. Silberg will help advance the Company’s patented platform technology for producing and preserving Stem Cell Factors (SCFs), a significant consumer opportunity.
Silberg is a seasoned professional in the pharmaceutical and biopharmaceutical industries with substantial executive level experience with large, medium-sized and startup biotechnology companies. His leadership skills have guided companies through organizational challenges ranging from building a startup biotech company to integrating a North America-based company with a European-based global healthcare organization. Before joining StemProtein, Silberg served as President and CEO of Genway Biotech Inc. Silberg’s position before Genway was CEO of APP North America, a wholly owned subsidiary of Fresenius Kabi, a global healthcare company based in Germany. He has also held COO positions for Tercica, Inc. and Ligand Pharmaceuticals Inc. His career began with Hoffmann La Roche Inc., where he started in sales and advanced to VP of Business Operations. Currently, in addition to his position on StemProtein’s board, he is a board director for CardioCell LLC, Pivotal Biosciences, StemCutis LLC, and serves as chairman of the board for Genway Biotech Inc. and the Palomar Health System Foundation. His past board appointments include the University of Southern California Center of Excellence in HealthCare Management, Medi Promotions, the Cobalis Corporation and the Generic Pharmaceutical Manufacturers Association. 
“StemProtein is in the unique position to capitalize on the health and beauty benefits derived from SCFs. I am excited to contribute to its growth by utilizing my experience and contacts in the health care industry to introduce our compositions into a variety of products,” Silberg commented, “Our primary goal is to manufacture and license the SCFs for use in ophthalmology, cosmetics, wound healing, skin damage, eye disease, cardiovascular and neurological conditions.”
Nikolai Tankovich, MD, PhD, President of Stemedica and Executive Chairman of StemProtein commented, “The potential of these beneficial SCFs to help OTC products including eye drops, nose drops, inhalable dry powders, injectable solutions and others, coupled with the exclusively licensed Vitrilife™ stabilizing technology, is very exciting.  Mr. Silberg will be working with major pharmaceutical companies from around the world to increase the competitiveness of their products with the addition of SCFs.”
About StemProtein, LLC
Founded in San Diego, California, StemProtein, LLC, is a global biotechnology company that develops pharmaceutical, cosmetic and dermatology compositions using stem cell factors. StemProtein is a subsidiary of Stemedica Cell Technologies, Inc., a cGMP-compliant facility that manufactures ischemia-tolerant allogeneic stem cells. The company’s technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians. StemProtein products are based on Stemedica’s unique, proprietary technology for the expansion of cells under hypoxic conditions, which provides critical benefits in terms of safety, efficacy, scalability and standardization. StemProtein has an exclusive, worldwide license from Stemedica to explore the use of SCFs for use in a variety of applications, including nasal and eye drops, intravenous injections, wound dressings and creams, and others. For more information, visit
About Stemedica Cell Technologies Inc. 
Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that manufactures best-in-class, allogeneic, adult stem cells and stem cell-derived factors. The company is a government-licensed manufacturer of cGMP, clinical-grade stem cells currently used in clinical trials for acute myocardial infarction, chronic heart failure, cutaneous photoaging and ischemic stroke. Stemedica’s products are also used by research institutions and hospitals for pre-clinical and clinical (human) trials. Under the auspices of the FDA and other international regulatory institutions, Stemedica is developing clinical trials for other indications using its adult, allogeneic stem cells. The company has headquarters in San Diego, California, and can be found online at
All media inquiries:
Fred Hill
The Townsend Team



SAN DIEGO—March 24, 2015—Stemedica Cell Technologies Inc., (Stemedica), announced today that Universal Stabilization Technologies (UST) has granted to Stemedica subsidiary StemProtein, LLC, an exclusive worldwide license to its technology known as Preservation by Vaporization (PBV) for industrial scale stabilization of stem cells and stem cell derivatives. This license will allow Stemedica and StemProtein to manufacture stem cell-secreted therapeutic proteins in a VitriLife™ state, that remain shelf stable and therapeutically active at ambient temperatures for two or more years.

“UST’s technology immediately accelerates Stemedica’s development of a wide range of products containing stem cell factors for consumer and medical markets worldwide,” said Nikolai Tankovich, MD, PhD, Stemedica’s President and Chief Medical Officer. “PBV significantly improves the bioactivity of preserved stem cell factors for reconstitution in many forms – from powders to gels, from bandages to liquids. PBV-preserved proteins are superior in activity compared to lyophilized proteins.” Stemedica products currently in development include eye drops, inhalable dry powders, wound dressings, injectable (parenteral) solutions, nose drops, sublingual tablets and a variety of skincare and dental products. “In addition to the significant consumer opportunities, we are optimistic about the role stabilized products may have in helping to treat a number of medical conditions including skin damage, eye diseases, cardiovascular and neurological conditions and in working to prevent or to slow down disease development such as Alzheimer’s disease,” said Dr. Tankovich.

UST’s Preservation by Vaporization is a unique technology that preserves the biological activity of stem cell proteins at room temperature and significantly cuts the time and cost of manufacturing compared to conventional methods of preservation while increasing final product yields as reconstituted in its various distribution and packaging forms. PBV technology provides an efficient process for converting stem cell factors into fine powders that retain their natural efficacy for eventual bulk processing and packaging of product for mass consumer and medical markets.

“I am pleased to enter into this collaboration with Stemedica,” said Victor Bronshtein, PhD, founder of Universal Stabilization Technologies and inventor of PBV. “Stemedica’s cGMP manufacturing and its unmatched command of commercial scale-up technologies are cornerstones for manufacturing pharmaceutical and over-the-counter products for consumer and medical markets.”

The patented PBV technology immobilizes biologicals in glassy carbohydrates (a VitriLife™ state) that enables its stable storage and shipping without refrigeration. PBV preserves a mixture of macromolecules that are secreted by stem cells in culture. The thermostable mixture contains sensitive biologicals, such as cytokines, chemokines, growth factors, matricellular proteins, enzymes, mRNAs and microRNAs.

“UST’s propriety dosage format will enable Stemedica’s preserved stem cell products to meet ambient temperature (-20°C to +40°C) shelf-life standards for a pharmaceutical or over-the-counter product,” said Yuri Kudinov, MD, PhD, Vice President of Research at StemProtein. “Thermostable stem cell products will ensure the confidence of patients and prescribing physicians that a product provides the therapeutic activity listed on the label, not merely at the time of manufacture, but at the time of use. This is not the case for many stem cell products now marketed through consumer channels.”